Introduction: coronavirus disease is now a global pandemic due to rapid human-to-human transmission. It can cause mild to fatal respiratory, cardiovascular, and neurological diseases. We aimed to find out whether elevated D-dimer levels are a predictor of the bad progression of COVID-19 to help reducing the mortality.

Methods: the data of COVID-19 patients from March 21, 2020 to April 24, 2020 were retrieved from the Cheick Khalifa Hospital database. We used the receiver operating characteristic (ROC) curve to get the optimum cutoff value of D-dimer levels on admission and after 5 days. We used these cutoffs to divide patients into two groups and compare the in-hospital mortality between them to assess the prognosis value of D-dimer levels.

Results: the data of COVID-19 patients from March 21, 2020 to April 24, 2020 were retrieved from the Cheick Khalifa Hospital database. We used the receiver operating characteristic (ROC) curve to get the optimum cutoff value of D-dimer levels on admission and after 5 days. We used these cutoffs to divide patients into two groups and compare the in-hospital mortality between them to assess the prognosis value of D-dimer levels.

Conclusion: D-dimer greater than 1360 ng/ml on day 5 could help clinicians identify patients with poor prognosis at an early stage of COVID-19.
Introduction

Since December 2019, a cluster of pneumonia has attacked all human beings [1]. The pathogen was designated as SARS-CoV-2 by the International Committee on Taxonomy of Viruses, and this pneumonia was named as Coronavirus Disease 2019 (COVID-19). This new infective outbreak has spread quickly all around the world [2]. The challenge was to find effective predictors of COVID-19 critical disease and death in order to identify critical patients early. Elevation of D-dimer indicated an hypercoagulable state in patient with Covid-19 and reflects activation of coagulation and fibrinolysis [3]. Recent literature data show that D-dimer values are frequently enhanced in non-survivor patients with COVID-19 [4,5]. In this article, we analyzed the prognostic value for D-dimer on admission and comparison to data in the past 5 days. This would help us predict the progression of the disease and adjust the treatment plan to reduce the risk of death.

Methods

Study design and participants: this retrospective study was conducted in Cheick Khalifa International University Hospital, Mohammed VI (Casablanca, Morocco). All adult patients (≥18 years old) who were diagnosed with COVID-19 according to WHO interim guidance, and confirmed by RNA detection of the SARS-CoV-2 in onsite clinical Laboratory, were screened. Our study enrolled all adult inpatients who were hospitalized for COVID-19 with D-dimer level on admission, five days later and a definite outcome (dead or discharged), between March 21, 2020 and April 24, 2020. Therefore, we excluded patients with incomplete data, leaving 89 includes of the 149 patients originally reported on. The study was approved by the Research Ethics Commission of Cheikh Khalifa Hospital and the requirement for informed consent was waived by the Ethics Commission.

Data collection: epidemiological, clinical, laboratory, and outcome data were extracted from electronic medical records using a standardized data collection form. All data were checked by two physicians (SA and SH) and a third researcher (SO) adjudicated any difference in interpretation between the two primary reviewers.

Laboratory assay and intervention: throat-swab specimens were obtained for SARS-CoV-2 PCR examination. The criteria for discharge were absence of fever for at least 3 days, clinical remission of respiratory symptoms, improvement in both lungs in chest CT, and a throat-swab samples negative for SARS-CoV-2 RNA obtained 24 h apart. Blood samples were collected within 24 hours after admission to perform routine laboratory tests, such as blood count, coagulation profile, renal and liver function, creatinine, lactate dehydrogenase, D-dimer and myocardial enzymes. A second blood sample was collected the fifth day to control D-dimer level. D-dimer was determined on VIDAS D-Dimer (Casablanca, Morocco). All adult patients (≥18 years old) who were hospitalized for COVID-19 with D-dimer level on admission, five days later and a definite outcome (dead or discharged), between March 21, 2020 and April 24, 2020. Therefore, we excluded patients with incomplete data, leaving 89 includes of the 149 patients originally reported on. The study was approved by the Research Ethics Commission of Cheikh Khalifa Hospital and the requirement for informed consent was waived by the Ethics Commission.

Data collection: epidemiological, clinical, laboratory, and outcome data were extracted from electronic medical records using a standardized data collection form. All data were checked by two physicians (SA and SH) and a third researcher (SO) adjudicated any difference in interpretation between the two primary reviewers.

Lanmary assay and intervention: throat-swab specimens were obtained for SARS-CoV-2 PCR examination. The criteria for discharge were absence of fever for at least 3 days, clinical remission of respiratory symptoms, improvement in both lungs in chest CT, and a throat-swab samples negative for SARS-CoV-2 RNA obtained 24 h apart. Blood samples were collected within 24 hours after admission to perform routine laboratory tests, such as blood count, coagulation profile, renal and liver function, creatinine, lactate dehydrogenase, D-dimer and myocardial enzymes. A second blood sample was collected the fifth day to control D-dimer level. D-dimer was determined on VIDAS D-Dimer (Casablanca, Morocco). All adult patients (≥18 years old) who were hospitalized for COVID-19 with D-dimer level on admission, five days later and a definite outcome (dead or discharged), between March 21, 2020 and April 24, 2020. Therefore, we excluded patients with incomplete data, leaving 89 includes of the 149 patients originally reported on. The study was approved by the Research Ethics Commission of Cheikh Khalifa Hospital and the requirement for informed consent was waived by the Ethics Commission.

Results

Baseline characteristics: 149 adult patients were hospitalized in Cheick Khalifa Hospital with COVID-19 between March 21, 2020 and April 24, 2020. After excluding 60 patients without available key information in their medical records, we included 89 inpatients in the final analysis. Ten patients died during hospitalization and 79 were discharged. The median age of the 89 patients was 48 years (IQR, 28–68 years), ranging from 18 years to 84 years, and most patients were male (Table 1). Comorbidities were present in nearly 44.9% of patients, with hypertension being the most common comorbidity, followed by diabetes and coronary heart disease. The most common symptoms on admission were fever, cough, headaches, followed by dyspnea and fatigue. Table 1 contains the basic characteristics of the patients. Among routine laboratory tests, D-dimer on Day 5 has the highest C-index to predict in-hospital mortality in COVID-19 patients. Besides, the C-indices indicates C-reaction protein and creatinine, are also strong predictors for these patients (Table 2).

High D-dimer levels to predict mortality: best cutoff points to predicting mortality in patient with COVID-19 using D-dimer levels on admission was 668 ng/ml (sensitivity 90%, specificity 63.3%%, area under ROC curve 0.775). As for D-dimer levels on day 5, it was 1360 ng/ ml (sensitivity 100%, specificity 88.6%, area under ROC curve 0.964). There were statistical differences among D-dimer levels on admission and on day 5 in terms of area under the ROC curve (p = 0.002) (Figure 1). According to the cutoff value, 55 patients D-dimer levels on admission were less than 668 ng/ml, 34 patients had D-dimer levels over 668 ng/ml. 69 patients had D-dimer levels on Day 5 less than 1360 ng/ml and 20 patients had D-dimer levels over 1360 ng/ml. A total of 10 death events occurred during hospitalization, nine of them were observed among patients with D-dimer levels ≥668 ng/ml on admission. Only one event occurred in patients with D-dimer levels (<668 ng/ml) on admission (9/34 vs. 1/55). As for D-dimer levels on day 5, we observed zero death in the group with D-dimer < 1360 ng/ml (10/20 vs 0/69). Kaplan-Meier Survival Curves for D-dimer, revealed that the group with D-dimer levels on day 5 > 1360 ng/ml had a worst evolution and a higher incidence of mortality compared to the first groups with D-dimer levels on day 5 < 1360 ng/ml (10/19 vs 0/69, P = 0.0002) (Figure 2). In addition, D-dimer levels on day 5 are significantly correlated with the D-dimer levels on admission (r=0.73, p<10-4) but D-dimer on admission and on day 5 failed to show any significant correlation with length of hospital stay (r=0.28 and r=0.29 respectively) (Figure 3).

Figure 1: ROC curve showing validity of D-Dimer values in predicting mortality for COVID-19 patients.
Table 1: baseline characteristics of 89 patients with COVID-19

| Variable                        | Total n = 89 | D-dimer on admission < 668 n = 55 | D-dimer on admission > 668 n = 34 | p-value | D-dimer on day 5< 1360 n = 69 | D-dimer on day 5> 1360 n = 20 | p-value |
|---------------------------------|--------------|-----------------------------------|-----------------------------------|---------|--------------------------------|--------------------------------|---------|
| Age-yr. (IQR)                   | 48 (28-68)   | 45 (25-65)                        | 52 (33-71)                        | 0.40    | 43 (23-63)                      | 57 (26-88)                      | 0.09    |
| Age > 65 yr-n (%)               | 26 (29.2)    | 13 (26)                           | 13 (33.3)                         | 0.45    | 17 (24.6)                       | 9 (45)                          | 0.078   |
| Female- n (%)                   | 39 (43.8)    | 20 (40)                           | 19 (48.7)                         | 0.41    | 30 (43.5)                       | 9 (45)                          | 0.9     |
| Underlying conditions-n (%)     | 40 (44.9%)   | 21 (20)                           | 19 (55)                           | 1.1     | 25 (36)                        | 15 (75)                        | 1.4     |
| Hypertension-n (%)              | 22 (25)      | 11 (22)                           | 11 (28.9)                         | 0.45    | 15 (22)                        | 7 (35)                          | 0.24    |
| Diabetes-n (%)                  | 12 (13.6)    | 7 (14)                            | 5 (13.2)                          | 0.90    | 6 (8.8)                        | 6 (30)                          | 0.015   |
| Coronary heart disease-n (%)    | 5 (5.7)      | 2 (5.3)                           | 3 (6)                             | 0.88    | 3 (4.4)                        | 2 (10)                          | 0.34    |
| Chronic kidney disease-n (%)    | 1 (1.1)      | 1 (2.6)                           | 0 (0)                             | 1.33    | 1 (1.5)                        | 0 (0)                           | 0.58    |
| Symptoms                        |              |                                   |                                   |         |                                |                                 |         |
| Fever-n (%)                     | 52 (58.4)    | 22 (56.4)                         | 30 (60)                           | 0.73    | 40 (58)                        | 12 (60)                         | 0.87    |
| Cough-n (%)                     | 51 (57)      | 20 (51.3)                         | 31 (62)                           | 0.31    | 42 (60.9)                      | 9 (45)                          | 0.20    |
| Headaches-n (%)                 | 26 (29.2)    | 11 (28.2)                         | 15 (30)                           | 0.85    | 21 (30.4)                      | 5 (25)                          | 0.63    |
| Dyspnea-n (%)                   | 24 (27.3)    | 8 (21.1)                          | 16 (32)                           | 0.25    | 17 (25)                        | 7 (35)                          | 0.37    |
| Fatigue-n (%)                   | 18 (20.2)    | 9 (23.1)                          | 9 (18)                            | 0.55    | 14 (20.3)                      | 4 (20)                          | 0.97    |
| Routine tests on admission      |              |                                   |                                   |         |                                |                                 |         |
| WBC- 10⁹/mm³ (IQR)              | 6.5 (4.09, 8.6) | 6.71 (4.56, 8.53) | 6.24 (4.2, 8.26) | 0.16    | 6.69 (4.8, 8.5)               | 6.8 (4.8, 8.8) | 0.760   |
| Hemoglobin-g/dl (IQR)           | 14 (12.7, 15.3) | 14.1 (12.6, 15.5) | 13.8 (12.5, 15.07) | 0.46    | 13.5 (12.7, 14.3)             | 14.2 (13.5, 14.9)             | 0.41    |
| Platelet- 10⁹/mm³ (IQR)         | 241 (164, 318) | 249 (174, 328) | 232 (153, 311)  | 0.07    | 229 (120, 338)               | 250 (177, 323)                | 0.6     |
| CRP- mg/L (IQR)                 | 43 (3, 107)  | 32 (2, 62)                        | 58 (3, 113)                       | 0.024   | 36 (4, 68)                     | 67 (5, 129)                    | 0.002   |
| Creatinine- mg/L (IQR)          | 9.3 (3.3, 15.3) | 8.77 (4.47, 13.07) | 11.18 (1.9, 20.3) | 0.001   | 10 (6.5, 14.5)              | 15.6 (2, 28)                  | <0.001  |
| D-dimer ng/ml on Day 5          | 1204 (1, 3300) | 555 (10, 1767) | 2011 (13, 4627) | <0.001  | /                            | /                             | /       |
| Severe COVID-19 - n (%)         | 37           | 12                                | 25                                | <0.001  | 19                            | 18                            | <0.0001 |
| Hospital stay days              | 12.3 (7.3, 17.3) | 10.4 (7, 13.8) | 14.8 (9, 20.6) | 0.008   | 11 (7, 15)                    | 17 (10, 25)                   | 0.005   |
| Non survivors-n (%)             | 10 (11.2)    | 1 (0.018)                         | 9 (26.4)                          | <0.001  | 0                             | 10                            | <0.001  |

Data are mean±SD, median (IQR), n (%). p values were calculated by t test, Mann-Whitney U test, χ² test, or Fisher’s exact test, as appropriate. IQR: interquartile range; CRP: C-reaction protein.

Table 2: C-statistic of routine tests to predict mortality in patients with COVID-19

| Routine laboratory tests            | C-index | 95% CI     |
|-------------------------------------|---------|------------|
| D-dimer on admission                | 0.775   | 0.674-0.857|
| D-dimer on Day 5                    | 0.946   | 0.876-0.982|
| C-reactive protein                  | 0.910   | 0.831-0.960|
| Platelet                            | 0.631   | 0.522-0.731|
| Creatinine                          | 0.824   | 0.729-0.927|
| White blood cells                   | 0.547   | 0.438-0.653|

CI: Confidential interval
Figure 2: Kaplan–Meier survival curves: (A) for D-dimer levels on admission ($p = 0.11$); (B) for D-dimer levels on day 5 ($P = 0.0002$)

Figure 3: Scatter graph showing correlation between D-dimer levels on admission and 5 days after admission ($r = -0.73; p < 0.0001$)
Discussion

This study showed that D-dimer on day 5 greater than 1360 ng/ml was associated with higher odds of in-hospital death. It was more commonly seen in severe COVID-19 illness as well. It confirmed that increased D-dimer levels on day 5 was a mortality predictor. The study established a cutoff value as well, to identify at an early stage the patients with COVID-19 who might suffer and have a bad prognosis. D-dimer dynamics can reflect the severity and their increased levels are associated with adverse outcomes among patients with community-acquired pneumonia [6]. Recent literature data show that D-dimer values are frequently enhanced in patients with COVID-19 and that it is even higher in patients with severe COVID-19 than in those with milder forms. Accordingly, abnormal D-dimer was detected in 36% of patients in a descriptive study of 99 COVID-19 cases in Wuhan, China [7]. Huang et al reported clinical and laboratory data of 41 patients hospitalized with confirmed COVID-19 and observed that D-dimer values were fivefold higher in those with severe disease (median: 2.4-mg/L; IQR: 0.6-14.4-mg/L) than in those without (median: 0.5 ng/mL; IQR: 0.3-3.8-mg/L; p¼ 0.004) [6]. Tang N et al found that non-survivors had a significantly higher D-dimer than that of survivors [4]. Wang et al included 138 patients hospitalized for COVID-19, D-dimer values were nearly 2.5-fold higher in patients with severe disease than in those without [8]. Zhou et al studied 191 patients with COVID-19 and found that D-dimer values were nearly ninefold higher in patients who died than in those who survived [9]. None of this studies provide well evaluated cutoff for D-dimer.

In a multicenter retrospective study during the first two months of the epidemic in China, 260 out of 560 patients (46.4%) with laboratory confirmed COVID-19 infection had elevated D-dimer (≥ 500 ng/ml). The cut-off (i.e., 500 ng/m) was locally defined. The risk of having D-dimer values above 500 ng/ml was more frequent in patients with severe disease than in those without [10]. Zhang et al extracted data on 343 patients enrolled in Wuhan with COVID-19. The cutoff value of 2000 ng/ml (fourfold increase) for D-dimer was established by ROC curve. D-dimer levels ≥2000 ng/ml had a higher incidence of mortality when comparing to those who with D-dimer levels < 2000 ng/ml [11]. In current study, a clear cutoff value (668 ng/ml on admission and 1360 ng/ml on day 5) for D-dimer was well established by ROC curve. We found that of the 10 non-survivors with D-dimers over 1360 ng/ml, three patients had no severity symptoms on admission. Nonetheless, what clearly emerges from this results is that even in the absence of other severity symptoms, patients who have high D-dimer levels over 1360ng/ ml on day five should be closely monitored. This highlighted the fact that D-dimer measurement may be associated with evolution toward worse clinical picture. In addition, we found a significant correlation between D-dimer levels on day 5 and D-dimer levels on admission. This means that serial measurement of D-dimer would help recognizing at an early stage, the COVID-19 patients who might have a poor prognosis.

In fact, elevation of D-dimer indicated a hypercoagulable state in patient with COVID-19 [12]. It can be attributed to many reasons. SARS-CoV-2 can cause direct myocardial injury. It infects cardiomyocytes by identifying ACE2 receptor [13]. Indirect injury may be caused by inflammatory storm. Various inflammatory factors produced by this storm might induce the dysfunction of endothelial cells, resulting in excess thrombin generation [14]. Current studies have shown that up to 20% of covid-19 patients have abnormal coagulation function [10]. The hypercoagulability of blood will increase the risk of thrombosis and embolization of the visceral causing ischemia and hypoxia, which leads to the progression of the disease to critical disease or death. In fact, critical covid-19 patient’s disease showed occlusion and micro-thrombosis formation in pulmonary small vessels [15]. Tang et al also recently reported that the vast majority of COVID-19 patients who died during hospital stay fulfilled the criteria for diagnosing sepsis-induced coagulopathy or disseminated intravascular coagulation [7.6 vs. 0.6% in survivors] [1]. To enhance the precision of scores for the identification of high venous thromboembolism (VTE) risk patients, a modified IMPROVE-VTE Risk Assessment Models which includes the D-dimers levels together with other clinical predictors of VTE was made [16-18]. This study has some limitations. First, interpretation of our findings might be limited by the sample size and the fact that it was a retrospective study. However, we believe we had enough information to find significant differences between the groups in mortality. Second, we excluded 60 patients for unavailable data (absence of D-dimer on admission). Some patients were even transferred late in their illness. This might have contributed to change the results. Third, by excluding patients still in hospital as of Apr 24, 2020, and thus relatively more severe disease at an earlier stage, the case fatality ratio in our study cannot reflect the true mortality of COVID-19.

Conclusion

D-dimer elevations may be commonplace in patients with severe forms of COVID-19 as in other severe infections disease. Their careful evaluation and monitoring could effectively predict in-hospital mortality in patients with COVID-19 at an early stage. This would assist clinicians in formulating a tailored treatment approach and promptly provide intensive care to those who are in greater need.

What is known about this topic

• Measuring D-dimer had been recommended for COVID-19 patients;
• The management of COVID-19 patients might be improved by finding early mortality markers.

What this study adds

• The optimal cutoff for D-dimer to predict in-hospital mortality for COVID-19;
• The prognosis value of D-dimer measurements on admission and after 5 days.

Competing interests

The authors declare no competing interests.

Authors’ contributions

SO drafted the manuscript. SO, SA, EB collected and analysed the data, SO and EB interpreted the data. SO, SA and MS designed the study. Critical revision of the manuscript for important intellectual content: SO, AE, EB, SH, IB, AN, MS. All authors read and approved the final manuscript.

References

1. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523.
2. Chih CL, Tzu PS, Wen CK, Hung JT. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Mar;55(3):105924.
3. Zhang L, Long Y, Xiao H, Yang J, Toulon P, Zhang Z. Use of D-dimer in oral anticoagulation therapy. Int J Lab Hematol. 2018 May 27.
4. Tang N Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-847.
5. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020 Jun;18(6):1324-1329.
6. Snijders D, Schoorl M, Schoorl M, Bartels PC, van der Werf TS, Boersma WG. D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial. Eur J Intern Med. 2012 Jul;23(5):436-441.
7. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513.
8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7;323(11):1061-1069.
9. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062.
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.
11. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020 Jun;18(6):1324-1329.
12. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-19 infection. Clin Chem Lab Med. 2020 Jun 25;58(7):1131-1134.
13. Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2373-9.
14. Harper PL, Theakston E, Ahmed J, Ockelford P. D-dimer concentration increases with age reducing the clinical value of the D-dimer assay in the elderly. Intern Med J. 2007 Sep;37(9):607-13.
15. M, van der Poll T. Coagulation and sepsis. Thrombosis research. 2017;149:38-44.
16. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034.
17. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24;323(13):1239-1242.
18. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al. A risk assessment model for the identification of hospitalised medical patients at risk for venous thromboembolism: the Padua Prediction Score. Journal of thrombosis and haemostasis. 2010;8(11):2450-7.